Vutrisiran significantly improved mortality, cardiovascular events and markers of disease progression in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.
Vutrisiran shows potential to become the new standard of care for rare heart disease
- Post author:
- Post published:August 30, 2024
- Post category:uncategorized